Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 42, 2009, Pages 17945-17950

  Bieging, Kathryn T ^a   Amick, Alexandra C ^a   Longnecker, Richard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Burkitt's lymphoma; Viral oncogenesis

Indexed keywords

LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; MYC PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER SURVIVAL; CARCINOGENESIS; EPSTEIN BARR VIRUS; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE MUTATION; IMMUNOBLOTTING; LYMPHOMAGENESIS; MOUSE; NONHUMAN; ONCOGENE MYC; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; DISEASE MODELS, ANIMAL; GENES, MYC; GENES, P53; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4; MUS;

EID: 70449566787     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0907994106     Document Type: Article

References (36)

1. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703.
2. Kelly GL, Rickinson AB (2007) Burkitt lymphoma: Revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007:277-284.
3. Dalla-Favera R, et al. (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824-7827. (Pubitemid 13182471)
4. Taub R, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837-7841. (Pubitemid 13182474)
5. Pelengaris S, Khan M, Evan G (2002) c-MYC: More than just a matter of life and death. Nat Rev Cancer 2:764-776. (Pubitemid 37328911)
6. Gaidano G, et al. (1991) p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413-5417. (Pubitemid 21914755)
7. Bhatia KG, Gutierrez MI, Huppi K, Siwarski D, Magrath IT (1992) The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52:4273-4276.
8. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T (1991) p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879-2887. (Pubitemid 21905305)
9. Newcomb EW (1995) P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 17:211-221.
10. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658-2669.
11. Zindy F, et al. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424-2433. (Pubitemid 28371361)
12. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27. (Pubitemid 29005019)
13. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101:6164-6169. (Pubitemid 38520545)
14. Eischen CM, Roussel MF, Korsmeyer SJ, Cleveland JL (2001) Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol 21:7653-7662.
15. Garrison SP, et al. (2008) Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 28:5391-5402.
16. Bell AI, et al. (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumor cells by using quantitative real-time PCR assays. J Gen Virol 87:2885-2890.
17. Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78:1697-1705. (Pubitemid 38176702)
18. Portis T, Longnecker R (2004) Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 23:8619-8628. (Pubitemid 39576469)
19. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W (2005) Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106:4339-4344. (Pubitemid 41775945)
20. Mancao C, Hammerschmidt W (2007) Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110:3715-3721. (Pubitemid 350159641)
21. Fukuda M, Longnecker R (2007) Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J Virol 81:9299-9306. (Pubitemid 47311472)
22. Anderson LJ, Longnecker R (2008) EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol 89:1563-1568.
23. Swanson-Mungerson MA, Caldwell RG, Bultema R, Longnecker R (2005) Epstein-Barr virus LMP2A alters in vivo and in vitro models of B-cell anergy, but not deletion, in response to autoantigen. J Virol 79:7355-7362. (Pubitemid 40756771)
24. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411.
25. Kovalchuk AL, et al. (2000) Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190.
26. Bultema R, Longnecker R, Swanson-Mungerson M (2009) Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28:1471-1476.
27. Caldwell RG, Brown RC, Longnecker R (2000) Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74:1101-1113.
28. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
29. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670-2677.
30. Schmitt CA, et al. (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289-298. (Pubitemid 41039153)
31. Chang DW, Claassen GF, Hann SR, Cole MD (2000) The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20:4309-4319.
32. Hemann MT, et al. (2005) Evasion of the p53 tumour surveillance network by tumor-derived MYC mutants. Nature 436:807-811.
33. Ikeda A, Merchant M, Lev L, Longnecker R, Ikeda M (2004) Latent membrane protein 2A, a viral B cell receptor homologue, induces CD5+ B-1 cell development. J Immunol 172:5329-5337. (Pubitemid 38542031)
34. Casola S, et al. (2004) B cell receptor signal strength determines B cell fate. Nat Immunol 5:317-327. (Pubitemid 38332129)
35. Swanson PJ, et al. (2004) Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc. J Immunol 172:6684-6691.
36. Fruehling S, et al. (1996) Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70:6216-6226. (Pubitemid 26266840)